BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9806508)

  • 1. Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer.
    D'Amico AV; Cormack R; Tempany CM; Kumar S; Topulos G; Kooy HM; Coleman CN
    Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):507-15. PubMed ID: 9806508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy.
    Thomas MD; Cormack R; Tempany CM; Kumar S; Manola J; Schneider L; Hurwitz MD; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):905-8. PubMed ID: 10863058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer.
    D'Amico A; Cormack R; Kumar S; Tempany CM
    J Endourol; 2000 May; 14(4):367-70. PubMed ID: 10910153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
    Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional real-time magnetic resonance-guided interstitial prostate brachytherapy optimizes radiation dose distribution resulting in a favorable acute side effect profile in patients with clinically localized prostate cancer.
    Hurwitz MD; Cormack R; Tempany CM; Kumar S; D'Amico AV
    Tech Urol; 2000 Jun; 6(2):89-94. PubMed ID: 10798806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy.
    Gómez-Iturriaga Piña A; Crook J; Borg J; Ma C
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):422-7. PubMed ID: 20832665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
    McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
    Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging.
    Zelefsky MJ; Cohen G; Zakian KL; Dyke J; Koutcher JA; Hricak H; Schwartz L; Zaider M
    Cancer J; 2000; 6(4):249-55. PubMed ID: 11038145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
    Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
    Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy.
    Zelefsky MJ; Yamada Y; Marion C; Sim S; Cohen G; Ben-Porat L; Silvern D; Zaider M
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):956-63. PubMed ID: 12605973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
    Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
    Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen spikes after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.